CTOs on the Move


 
Invetx is building the world’s premier biotechnology platform for protein-based therapeutics in animal health. We partner with best-in-class biotechnology companies to apply their deep expertise and extensive capabilities for the discovery and development of novel and advanced veterinary biotherapeutics.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.invetx.com
  • 201 Washington Street Suite 3930
    Boston, MA USA 02108
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Invetx raised $15M on 02/24/2020
Invetx raised $60.5M on 05/10/2022

Similar Companies

AllStripes

AllStripes is a healthcare technology company dedicated to unlocking new treatments for people with rare diseases. AllStripes has developed a technology platform that generates regulatory-ready evidence to accelerate rare disease research and drug development, as well as a patient application that empowers patients and families to securely participate in treatment research online and benefit from their own medical data. AllStripes was founded by CEO Nancy Yu and technology developer Onno Faber, following his diagnosis and journey with the rare disease neurofibromatosis type 2. The company is backed by Lux Capital, JAZZ Venture Partners, Spark Capital, Medidata Solutions, McKesson Ventures, Maveron, and a number of angel investors.

OraPharma , Inc.

OraPharma , Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

AIkido Pharma

AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics.

Taiga Biotechnologies Inc

Taiga Biotechnologies is a privately-held developer of novel therapies for complex diseases including cancers, infectious agents such as HIV and influenza, and hematologic conditions.

GPB Scientific

GPB Scientific is transforming the process of purifying and enriching cells for cell therapy production. Reliable cell recovery and expansion are fundamental to the successful scale up of CAR-T or any therapeutic cell manufacturing process. GPB has developed a high-throughput, automatable, microfluidic closed-system for leukapheresis sample preparation and downstream processing of cells for CAR-T and other cell therapy production. This breakthrough reduces cell losses and skill-intensive manual steps.